Nursing startup Trusted Health announced that it scored a whopping $149 million in funding. The funding breaks down to $94 million from a Series C round led by Greenspring Associates and an unannounced $55 million Series B round that was led by Craft Ventures and Felicis Ventures.
Today the San Francisco-based startup boasts a total of $175 million in funding. The company has created a nurse staffing platform called Works, which is focused on filling nursing shifts. Trusted Health lets employers create an on-demand workforce from internal and external sources in one system. The system can help in predicting staffing demands and in onboarding staff.
This new infusion of cash is expected to help the company speed up the rollout of Works.
“The pandemic exacerbated what we already knew: Healthcare staffing is in a crisis, and previous attempts to modernize the workforce have fallen short. We’ve been left with a fragmented ecosystem of apps and services for healthcare institutions trying to solve one problem: matching the right clinician to the right role in the most efficient manner,” Trusted’s CEO and cofounder Lennie Silwinski said in a statement.
“Through a combination of technology and close working relationships with organizations like Mercy, we’ve built a platform that is going to help hospitals meet staffing challenges head-on so they can keep their focus on delivering quality patient care.”
This morning RenalSense, an Israeli digital health startup focused on renal diagnostics, scored $14 million in Series A funding. BlueRed Partners Fund led the round.
The new funds will go towards commercializing a product called Clarity RMS and working on the next generation of its sensor-platform-based products. Clarity RMS was designed to help monitor patients in critical care and detect any changes in their renal function, as well as their acute kidney injury risk.
Looking down the road, the company said that it plans on creating more sensor-based products that can provide diagnostic data on the renewal system and other vital organ functions.
Fertility-focused insurtech company InsurMedix has raised $15 million, the first portion of its $65 million funding round. A-Labs Advisory & Finance Ltd. led the round.
The company has created an insurtech platform specifically for fertility. The platform, which is expected to launch in 2022, will offer policies for fertility and IVF treatments. Members will also be able to tap into complementary and alternative medicine and outbound medical tourism.
When the company launches, customers in the U.S. will be able to join for a monthly subscription fee.
“Our platform will offer a wide variety of insurance products at extremely affordable subscription prices, in a market that requires such products for the past decades, with no avail,” Darren Gradus, the company’s CEO, said in a statement.
“We made it our prime target to become the largest medical insurtech player in the U.S. over the next five years, and we bring hope to those who cannot afford these important treatments.”